While NSCLC patients with EGFR and ALK mutations show relatively improved survival compared with those with wild-type EGFR and ALK22,23, determining the prognostic value of the PLR in wild-type EGFR and ALK lung cancer would be meaningful. This evidence concerns the gene ALK and lung carcinoma.